News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients
Nov 30, 2024, 16:08

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared on X:

“Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients: iScience

Authors: Rasmus Virenfeldt Flak, Emil Kofod-Olsen, Nikolaj Dich Sølvsten, Gintare Naujokaite, Ralf Agger, Mogens Tornby Stender, Signe Christensen, Susy Shim, Laurids Østergaard Poulsen, Sönke Detlefsen, Ole Thorlasius-Ussing, Morten Ladekar

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

When you combine one ineffective therapy in pancreatic cancer (aPD1) with another (IRE), the cumulative result is still ineffective. Everyone progressed right through it.”

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.

Anirban Maitra cancer Emil Kofod-Olsen Gintare Naujokaite Laurids Østergaard Poulsen Liver metastasis Mogens Tornby Stender Morten Ladekar Nikolaj Dich Sølvsten Ole Thorlasius-Ussing OncoDaily Oncology Pancreatic Cancer Ralf Agger Rasmus Virenfeldt Flak Signe Christensen Sönke Detlefsen Susy Shim
Special Coverage
Blog
Jan 6, 2025, 10:45
Megan-Claire Chase: Warrior Megsie… the SUPERHERO
Science
Jan 6, 2025, 10:42
Malte Roerden: How different immune evasion mechanisms interfere with immunoediting of evolving tumors
Blog
Jan 6, 2025, 10:41
Roupen Odabashian: The second lesson in my series on using AI to enhance learning
Blog
Jan 6, 2025, 10:39
Sachin H. Jain: In 2025, I urge you to start seeing things clearly
Positive
Jan 6, 2025, 10:36
As we begin 2025, we express our deepest gratitude to all of our supporters - The Max Foundation
Insight
Jan 6, 2025, 10:31
Immunosuppression in the Lung, New Mathematical Models and More - AACR
Insight
Jan 6, 2025, 10:15
Nelson Dusetti: New therapeutic avenues for new therapeutic avenues for improving PDAC treatment
Insight
Jan 6, 2025, 10:03
Ravi Parikh: TrialTranslator - a machine learning framework for individualized cancer trial emulation
Blog
Jan 6, 2025, 09:57
Sarah Louden: The start of a New Year often brings a surge of ambition mixed with anxiety
Blog
Jan 6, 2025, 09:54
Timothy Rebbeck: Public health messaging about the risks of cancer associated with alcohol consumption
Insight
Jan 6, 2025, 09:48
Amy Moore: PD-1/VEGF combos are a strategy to watch in lung cancer
Blog
Jan 6, 2025, 09:45
The ESO College is supporting with financial aid for the registration fees of examinations